Share:
NEW YORK, April 28, 2021 (GLOBE NEWSWIRE) Apollo Global Management, Inc. (NYSE:APO) (together with its consolidated subsidiaries, Apollo ) announced today that it will host a conference call to review Apollo s financial results on Tuesday, May 04, 2021 at 8:30 a.m. EST as previously stated. The Company has amended the timing of releasing its first quarter 2021 results to Tuesday, May 04, 2021 at 7 a.m. EST.
The conference call may be accessed by dialing (833) 614-1406 (U.S. domestic) or +1 (914) 987-7127 (international), and providing conference call ID 5576528 when prompted by the operator. The number should be dialed at least ten minutes prior to the start of the call. A simultaneous webcast of the conference call will be available to the public on a listen-only basis and can be accessed through the Stockholders section of Apollo s website at www.apollo.com.
Oncopeptides publishes the 2020 Annual Report
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Oncopeptides publishes the 2020 Annual Report
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
MidCap Financial Announces $800 Million Equity Raise
New and existing investors commit capital to help fund growth of middle market leader
News provided by
Share this article
Share this article
BETHESDA, Md., April 22, 2021 /PRNewswire/ MidCap Financial, a credit solutions firm focused on serving the middle market, today announced it has raised more than $800 million of new equity from a diverse group of global investors that included Apollo clients, including Athene as well as pensions, sovereign wealth funds and other leading institutions.
Proceeds from the raise will be used to fund business growth and for general corporate purposes. MidCap primarily focuses on senior debt solutions to companies across all industries, and as of December 31, 2020 has provided management or other services for approximately $29.8 billion of commitments, of which $5 billion is managed by MidCap Financial Services Capital Management LLC, a registered investment officer.
Oncopeptides submits application for conditional marketing authorization of melflufen in the EU
News provided by
Share this article
Share this article
STOCKHOLM, April 16, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the Company has submitted an application to the European Medicines Agency, EMA, for conditional marketing authorization of melflufen (melphalan flufenamide) in the EU, based on the pivotal phase 2 HORIZON study in relapsed refractory multiple myeloma. Pending a positive validation from the EMA, melflufen will be subject to a regulatory assessment according to the standard timelines.